CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

被引：7
|
作者：
Ramachandran, Raja [1 ]
Yadav, Ashok K. [1 ]
Kumar, Vinod [1 ]
Gupta, Krishan L. [1 ]
Kohli, Harbir S. [1 ]
机构：
[1] PGIMER, Dept Nephrol, Chandigarh, India
来源：
KIDNEY INTERNATIONAL REPORTS | 2017年 / 2卷 / 01期
关键词：
D O I：
10.1016/j.ekir.2016.08.019
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 90
页数：2
相关论文
共 23 条
  • [1] CD19 Repopulation and Anti-phospholipase A2 Receptor (PLA2R) following Rituximab in Membranous Nephropathy
    Kanigicherla, Durga Anil K.
    Hamilton, Patrick
    Shukkur, Meshaal Mohemed
    Thet, May Kyaw
    Ragy, Omar Sherin
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [2] Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD
    Hanset, Nicolas
    Esteve, Emmanuel
    Plaisier, Emmanuelle
    Johanet, Catherine
    Michel, Pierre-Antoine
    Boffa, Jean-Jacques
    Fievet, Patrick
    Mesnard, Laurent
    Morelle, Johann
    Ronco, Pierre
    Dahan, Karine
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (03): : 331 - 338
  • [3] Personalized phospholipase A2 receptor antibody-driven rituximab treatment strategy in membranous nephropathy
    Delafosse, Marion
    Ponlot, Eleonore
    Esteve, Emmanuel
    Ghislain, Louise
    Hanset, Nicolas
    Boffa, Jean-Jacques
    Johanet, Catherine
    Dahan, Karine
    KIDNEY INTERNATIONAL, 2021, 99 (04) : 1023 - 1024
  • [4] Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy
    Zhang, Lihua
    Chen, Mengxing
    Le, Weibo
    Zhang, Mingchao
    Tu, Yuanmao
    Zuo, Ke
    Chen, Dacheng
    Wu, Yan
    Li, Shijun
    Zeng, Caihong
    Cheng, Zhen
    Xie, Honglang
    IMMUNOTHERAPY, 2022, 14 (15) : 1237 - 1244
  • [5] Obinutuzumab in Refractory Phospholipase A2 receptor-Associated Membranous Nephropathy With Severe CKD
    Naik, Sachin
    Shukla, Shubham
    Niranjan, A., V
    Kumar, Vinod
    Sekar, Aravind
    Nada, Ritambhra
    Rathi, Manish
    Kohli, Harbir Singh
    Ramachandran, Raja
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 942 - 943
  • [6] Serum Phospholipase A2 Receptor Antibody Is Associated with Thrombogenesis in Patients with Idiopathic Membranous Nephropathy
    Zhang, Qinling
    Liu, Guiling
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01): : 490 - 494
  • [7] Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy
    Vink, Coralien H.
    van de Logt, Anne-Els
    van der Molen, Renate G.
    Hofstra, Julia M.
    Wetzels, Jack F. M.
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (03): : 432 - 441
  • [8] Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody
    Dahan, K.
    Johannet, C.
    Esteve, E.
    Plaisier, E.
    Debiec, H.
    Ronco, P.
    KIDNEY INTERNATIONAL, 2019, 95 (01) : 233 - 234
  • [9] Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
    Ruggenenti, Piero
    Debiec, Hanna
    Ruggiero, Barbara
    Chianca, Antonietta
    Pelle, Timothee
    Gaspari, Flavio
    Suardi, Flavio
    Gagliardini, Elena
    Orisio, Silvia
    Benigni, Ariela
    Ronco, Pierre
    Remuzzi, Giuseppe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (10): : 2545 - 2558
  • [10] Screening for Anti-Rituximab Antibody in Management of Rituximab Refractory PLA2R-Associated Membranous Nephropathy
    Ositelu, Ayotunde
    Vissing, Andrew
    Ayoub, Wadah J.
    Peleg, Yonatan A.
    Kanwar, Yashpal S.
    Aggarwal, Vikram
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 505 - 506
123